Lexeo Therapeutics (LXEO) Enterprise Value (2023 - 2026)

Lexeo Therapeutics has reported Enterprise Value for 5 years, with the latest figure at -$193.0 million in Q1 2026.

• Quarterly Enterprise Value fell 93.37% year-over-year to -$193.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$193.0 million (down 93.37% YoY) and the FY2025 annual result came in at -$181.8 million, down 49.58% from the prior year.
• Enterprise Value declined to -$193.0 million in Q1 2026 per LXEO's latest filing, from -$181.8 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$35.4 million in Q3 2023 and troughed at -$195.1 million in Q1 2024.
• A 5-year average of -$131.3 million and a median of -$122.8 million in 2025 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2023 and 2024: Enterprise Value jumped 62.35% in 2023, then tumbled 342.89% in 2024.
• Over 5 years, Enterprise Value stood at -$77.3 million in 2022, then plunged by 57.06% to -$121.5 million in 2023, then slipped by 0.04% to -$121.5 million in 2024, then sank by 49.58% to -$181.8 million in 2025, then decreased by 6.2% to -$193.0 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$193.0 million, -$181.8 million, and -$122.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.